Pharmacokinetics of recombinant interleukin 2 in humans.
Michael Konrad(University of Vienna), Edward C. Bradley(Incyte (United States)), George P. Hemstreet(University of Oklahoma), Peter W. A. Mansell(The University of Texas MD Anderson Cancer Center), Evan M. Hersh, Roland Mertelsmann(Unknown), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center)
Unknown
April 1, 1990
Cited by 216
Related Papers
Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells
|Science|1986|1.2k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor.
|Proceedings of the National Academy of Sciences|1985|522
Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology
|Annals of Hematology|2004|488